Genome-wide studies in prostate cancer poised liquid biopsy as a molecular discovery tool.
deep genomic sequencing
disease progression
genome-wide methylation analysis
liquid biopsy
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
03
2023
accepted:
10
08
2023
medline:
11
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Liquid biopsy is emerging as an intriguing tool in clinical disease detection and monitoring. Compared to a standard tissue biopsy, performing a liquid biopsy incurs minimal invasiveness, captures comprehensive disease representation, and can be more sensitive at an early stage. Recent genome-wide liquid biopsy studies in prostate cancer analyzing plasma samples have provided insights into the genome and epigenome dynamics during disease progression. In-depth genomic sequencing can offer a comprehensive understanding of cancer evolution, enabling more accurate clinical decision-making. Furthermore, exploring beyond the DNA sequence itself provides opportunities to investigate the regulatory mechanisms underlying various disease phenotypes. Here, we summarize these advances and offer prospects for their future application.
Identifiants
pubmed: 37692852
doi: 10.3389/fonc.2023.1185013
pmc: PMC10484097
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1185013Informations de copyright
Copyright © 2023 Lo, He and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Med. 2022 Feb 7;20(1):54
pubmed: 35125113
J Clin Invest. 2020 Apr 1;130(4):1991-2000
pubmed: 32149736
Biomedicines. 2021 Sep 08;9(9):
pubmed: 34572366
Clin Biochem. 2023 Jun;116:120-127
pubmed: 37121562
Cancers (Basel). 2022 Mar 29;14(7):
pubmed: 35406500
Med Clin North Am. 2011 Jan;95(1):191-200
pubmed: 21095422
Sci Rep. 2021 Jul 23;11(1):15052
pubmed: 34302010
Urol Oncol. 2016 Nov;34(11):483.e9-483.e16
pubmed: 27658563
Ann Oncol. 2020 Jun;31(6):745-759
pubmed: 33506766
Mod Pathol. 2021 Dec;34(12):2168-2174
pubmed: 34362997
Nat Rev Urol. 2013 Feb;10(2):99-107
pubmed: 23318363
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445
pubmed: 30664734
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
Cancer Res. 1999 Dec 1;59(23):5975-9
pubmed: 10606244
J Clin Oncol. 2013 Jan 1;31(1):17-22
pubmed: 23129736
Ann Oncol. 2023 Jan;34(1):111-120
pubmed: 36208697
JAMA Oncol. 2016 Jul 1;2(7):882-9
pubmed: 27032035
Clin Cancer Res. 2007 Apr 1;13(7):2023-9
pubmed: 17404082
Radiat Oncol. 2020 Jun 1;15(1):137
pubmed: 32487218
Prostate. 2022 Apr;82(5):584-597
pubmed: 35084050
Eur Urol. 2018 Sep;74(3):283-291
pubmed: 29500065
Urology. 2012 Dec;80(6):1328-32
pubmed: 23063057
Nat Commun. 2020 Oct 8;11(1):5070
pubmed: 33033260
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Front Oncol. 2022 Nov 10;12:1054497
pubmed: 36439451
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Eur J Cancer. 2017 Jan;70:122-132
pubmed: 27914242
Cells. 2020 May 31;9(6):
pubmed: 32486483
Ann Oncol. 2021 Jun;32(6):726-735
pubmed: 33794293
Ann Oncol. 2017 Jul 01;28(7):1508-1516
pubmed: 28472366
Genome Med. 2018 Nov 21;10(1):85
pubmed: 30458854
Clin Cancer Res. 2020 Aug 1;26(15):4143-4153
pubmed: 32341031
Science. 2009 May 15;324(5929):930-5
pubmed: 19372391
Nature. 2022 Aug;608(7921):199-208
pubmed: 35859180
Int J Mol Sci. 2019 Mar 19;20(6):
pubmed: 30893936
Nat Commun. 2022 Dec 3;13(1):7475
pubmed: 36463275
Nat Commun. 2022 Oct 29;13(1):6467
pubmed: 36309516
J Cancer Res Clin Oncol. 2013 May;139(5):755-63
pubmed: 23358719
Cancer Cell. 2019 Oct 14;36(4):350-368
pubmed: 31614115
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):339-342
pubmed: 28417979
Urol Oncol. 2016 May;34(5):235.e11-6
pubmed: 26795608
Eur Urol. 2018 Dec;74(6):731-738
pubmed: 30237023
Clin Cancer Res. 2021 Aug 1;27(15):4221-4229
pubmed: 34088722
Nature. 2020 Mar;579(7800):567-574
pubmed: 32214244
J Clin Invest. 2020 Apr 1;130(4):1653-1668
pubmed: 32091413
Clin Epigenetics. 2019 Dec 2;11(1):175
pubmed: 31791387
Cancer Discov. 2023 Mar 1;13(3):632-653
pubmed: 36399432
Sci Transl Med. 2010 Mar 31;2(25):25ra23
pubmed: 20424012
J Urol. 2008 May;179(5):1804-9; discussion 1809-10
pubmed: 18353398
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
J Urol. 2008 Jun;179(6):2187-91; discussion 2191
pubmed: 18423725
Res Rep Urol. 2022 Mar 01;14:63-70
pubmed: 35257006
J Clin Oncol. 2015 Apr 20;33(12):1348-55
pubmed: 25800753
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Ann Oncol. 2021 Jun;32(6):694-695
pubmed: 33839261
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258
Eur Urol. 2019 Apr;75(4):667-675
pubmed: 30638634
Clin Cancer Res. 2020 Mar 1;26(5):1114-1125
pubmed: 31744831
NPJ Precis Oncol. 2023 Mar 13;7(1):27
pubmed: 36914848
Prostate. 2008 Jan 1;68(1):42-9
pubmed: 18004747
J Oncol. 2010;2010:617421
pubmed: 20016752